How to buy Travere Therapeutics stock

Travere Therapeutics, Inc is a biotechnology business based in the US. Travere Therapeutics shares (RTRX) are listed on the NASDAQ and all prices are listed in US Dollars. Travere Therapeutics employs 221 staff and has a trailing 12-month revenue of around USD$194 million.

How to buy shares in Travere Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Travere Therapeutics. Find the stock by name or ticker symbol: RTRX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Travere Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Travere Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Travere Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Our top pick for

Beginners

Robinhood

Our top pick for

Active investors

Webull

Our top pick for

Building a portfolio

Sofi Invest

How we chose our top picks

We evaluate stock trading platforms against a range of metrics that include fees, ease of use, available securities and advanced tools to meet specific investor needs. We encourage you to compare stock platforms to find one that's best for your particular budget and goals.

• Our pick for beginners. We chose Robinhood for this category because it offers commission-free trading and is easy to use. You can search for stocks by company name, and the mobile app is clean and intuitive to use.
• Our pick for active investors. We picked Webull for this category because its platform offers features that cater to advancing investors as well as beginners. The desktop app is outfitted with an extensive set of research tools, the mobile app gets high grades from users and traders can test strategies with a paper-trading feature.
• Our pick for building a portfolio. We chose SoFi for this category because it offers both commission-free stocks and a free robo-advisor. That means you can open an active investing account to pick and choose companies you want to invest in, and open a robo-advisor account to help you build a portfolio and manage how much risk you take on.

What's in this guide?

1. RTRX shares summary
2. Compare share dealing platforms
3. Is RTRX stock a buy or sell?
4. Stock performance over time
5. Can I short RTRX shares?
6. Travere Therapeutics's financials
7. How volatile are RTRX shares?
8. Does Travere Therapeutics pay a dividend?
9. Have RTRX shares ever split?
10. Other common questions

Travere Therapeutics share price

Use our graph to track the performance of RTRX stocks over time.

Travere Therapeutics shares at a glance

• Key figures

Information last updated 2021-01-22.

52-week range	USD$8.98 - USD$25.5
50-day moving average	USD$23.9526
200-day moving average	USD$20.3382
Wall St. target price	USD$31.38
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-3.417

Buy Travere Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Sort by:

Name	Product	Stock trade fee	Asset types	Option trade fee	Annual fee	Signup bonus
Robinhood		$0	Stocks, Options, ETFs, Gold/Commodities	$0	0%	Free stock (chosen randomly with a value anywhere between $2.50 and $200) Sign up using the "go to site" link	Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.	Go to site More Info		loading Fetching your data...
Webull		$0	Stocks, Options, ETFs	$0	0%	Get two free stock valued between $2.50 and $250 Open an account	Margin financing rates start at 3.99%. No monthly subscription fees for margin.	Go to site More Info		loading Fetching your data...
TradeStation		$0	Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency	$0 + $0.50/contract		$50 Deposit qualifying assets of $5,000+	A platform built for all kinds of traders and all styles of trading	Go to site More Info		loading Fetching your data...
Tastyworks		$0	Stocks, Options, Cryptocurrency	Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg Futures: $2.50/contract to open, $0 to close	0%	Get 100 shares of stock (worth $1 to $6 a share) Open and fund a new cash or margin account with $2,000+	Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.	Go to site More Info		loading Fetching your data...
Interactive Brokers		$0	Stocks, Bonds, Options, Mutual funds	$0 + $0.65/contract, $1 minimum	0%	N/A	IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.	Go to site More Info		loading Fetching your data...

loading

Compare up to 4 providers

Clear selection

Compare

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Travere Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Travere Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Shorting Travere Therapeutics shares

There are currently 4.8 million Travere Therapeutics shares held short by investors – that's known as Travere Therapeutics's "short interest". This figure is 1.6% up from 4.7 million last month.

There are a few different ways that this level of interest in shorting Travere Therapeutics shares can be evaluated.

Travere Therapeutics's "short interest ratio" (SIR)

Travere Therapeutics's "short interest ratio" (SIR) is the quantity of Travere Therapeutics shares currently shorted divided by the average quantity of Travere Therapeutics shares traded daily (recently around 265521.38121547). Travere Therapeutics's SIR currently stands at 18.1. In other words for every 100,000 Travere Therapeutics shares traded daily on the market, roughly 18100 shares are currently held short.

However Travere Therapeutics's short interest can also be evaluated against the total number of Travere Therapeutics shares, or, against the total number of tradable Travere Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Travere Therapeutics's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Travere Therapeutics shares in existence, roughly 90 shares are currently held short) or 0.104% of the tradable shares (for every 100,000 tradable Travere Therapeutics shares, roughly 104 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Travere Therapeutics.

Find out more about how you can short Travere Therapeutics stock.

Have Travere Therapeutics's shares ever split?

Travere Therapeutics's shares were split on a 1:9 basis on 8 November 2011. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Travere Therapeutics shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Travere Therapeutics shares which in turn could have impacted Travere Therapeutics's share price.

Travere Therapeutics share price volatility

Over the last 12 months, Travere Therapeutics's shares have ranged in value from as little as $8.98 up to $25.5. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Travere Therapeutics's is 0.721. This would suggest that Travere Therapeutics's shares are less volatile than average (for this exchange).

Travere Therapeutics overview

Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.

Frequently asked questions

• What percentage of Travere Therapeutics is owned by insiders or institutions?

  Currently 0.895% of Travere Therapeutics shares are held by insiders and 104.799% by institutions.

• How many people work for Travere Therapeutics?

  Latest data suggests 221 work at Travere Therapeutics.

• When does the fiscal year end for Travere Therapeutics?

  Travere Therapeutics's fiscal year ends in December.

• Where is Travere Therapeutics based?

  Travere Therapeutics's address is: 3721 Valley Centre Drive, San Diego, CA, United States, 92130

• What is Travere Therapeutics's ISIN number?

  Travere Therapeutics's international securities identification number is: US7612991064

• What is Travere Therapeutics's CUSIP number?

  Travere Therapeutics's Committee on Uniform Securities Identification Procedures number is: 250392305